CME CirclePrint this Activity for Offline ReferenceInstructions on Taking Medscape CME

Ovarian Cancer Management: An Update Focusing on Efficacy and Toxicity of Therapy CME
Faculty: Chairperson: Maurie Markman, MD; Faculty: Lois Almadrones, RN, MS, CFNP, MPA; Alan N. Gordon, MD; David R. Spriggs, MD; J. Tate Thigpen, MD
Disclosures

Release Date: March 29, 2002; Valid for credit through March 29, 2003

This activity has expired.
CME in this activity indicates that it was developed according to ACCME guidelines and was certified for credit by one or more accredited CME or CE providers. Medscape cannot attest to the timeliness of expired CME activities.


This CME activity is based on transcripts and slides of presentations as delivered by the faculty during the "Ovarian Cancer Management: An Update Focusing on Efficacy and Toxicity of Therapy" broadcast on December 6, 2001.

Contents of This CME Activity
  1. Current Standards of Care in the Management of Ovarian Cancer
    Overview

  2. Novel Agents in the Treatment of Ovarian Cancer
    Cancer Cell Targets
    Growth Factor Receptor Targets
    Ansamycins
    Proteasome Inhibition and Kinase Inhibitors
    Epothilone B Analog

  3. Update on the Phase III Trial Comparing Pegylated Liposomal Doxorubicin vs Topotecan as Second-Line Treatment of Ovarian Cancer
    Pegylated Liposomal Doxorubicin
    Phase III Study Background: Pegylated Liposomal Doxorubicin vs Topotecan
    Phase III Study: Time to Progression
    Phase III Study: Response Data
    Phase III Study: Overall Survival
    Phase III Study: Adverse Events
    Phase III Study: Miscellaneous Data and Conclusions

  4. Multi-Center 5-Arm Randomized Trial of Initial Chemotherapy for Advanced Ovarian Cancer
    Ovarian Cancer Staging
    Rationale for Gynecologic Oncology Group (GOG) Protocol 182: Looking at GOG Protocol 111
    Rationale for Gynecologic Oncology Group (GOG) Protocol 182: Looking at Protocol OV-10
    Studies of Cisplatin vs Carboplatin
    Focusing on Dose Intensity
    Current Standard of Care for Ovarian Cancer
    A Study of Paclitaxel, Epirubicin, and Carboplatin vs Paclitaxel and Carboplatin
    GOG Protocol 132 and Further Areas of Study

  5. Toxicity Management for Chemotherapeutic Agents Used in the Treatment of Ovarian Cancer
    Interventions for Short-Term Toxicity in Ovarian Cancer
    Addressing and Managing Hypersensitivity Reactions
    Managing Long-Term Sequelae of Treatment With Glutamine
    Managing Neuropathic Pain
    Autonomic Neuropathy
    Support Groups for Patients

These educational activities, certified by accredited providers, were not prepared by Medscape's editors, but are made available on our site as a service to our audience. Authors are routinely instructed by the provider to disclose significant financial relationships and mention of investigational drugs and unapproved indications. Medscape has received a fee for posting these activities. Direct questions or comments to: CME@webmd.net.

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape, the CME provider, the companies providing educational grants or the authors and writers. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers and continuing education participants should verify all information and consult a qualified healthcare professional before treating patients or utilizing any therapeutic product discussed in this educational activity.

 
Copyright © 2002 HMP Communications, LLC (HMP)
Orthobiotech
  • This activity has expired.

    The accredited provider can no longer issue certificates for this activity. Medscape cannot attest to the timeliness of expired CME activities.

  • CME Information
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.